As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

On Tuesday, his company, Variant Bio, based in Seattle, announced a $50 million collaboration with drugmaker Novo Nordisk to develop drugs for metabolic disorders, including diabetes and obesity ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.

SEATTLE, WA, USA I January 7, 2025 I Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the ...

U.S.-listed shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are up 3.5% premarket, following a bull note from UBS. The analyst in question upgraded NVO to "buy" from "neutral ...